Form 4: Adial Pharmaceuticals COO Tony Goodman Acquires Stock Options
SEC Form 4 Filing
Tony Goodman, Chief Operating Officer of Adial Pharmaceuticals, acquired 42,000 stock options on March 25, 2024.
Summary
- On March 25, 2024, Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, acquired 42,000 stock options.
- The options have an exercise price of $1.35.
- The options vest pro rata on a monthly basis over 36 months, starting April 25, 2024.
- The options expire on March 24, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation packages.
Stakeholder Impact
- The granting of stock options aligns management's interests with those of shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Tony Goodman acquired 42,000 stock options. |
| 04/25/2024 | Commencement date for monthly vesting of the stock options over 36 months. |
| 03/24/2034 | Expiration date of the stock options. |
| 03/27/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, insider trading, Adial Pharmaceuticals, Tony Goodman, COO, ADIL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.